

BÖLÜM 24

Metastatik Prostat Kanserinde Moleküler Hedefli Tedaviler

Harun MUĞLU¹

GİRİŞ

Metastatik prostat kanserinin tedavi yelpazesi son iki dekatta önemli ölçüde gelişti. Birkaç dönüm noktası niteliğindeki faz 3 denemeler, yeni geliştirilen ilaçlar ile tedavi seçeneklerinde hızlı değişikliklere yol açtı. Bu ilaçlar, farklı etki mekanizmalarına (hormonal, kemoterapi, radyonüklid, immünoterapi ve hedefe yönelik terapiler gibi) sahip ilaçları içerir(1).

Hastalığın ileri evrelerinde (metastatik kastrasyona dirençli prostat kanseri) geliştirilen tedaviler, daha erken evrelerine (metastatik hormon naif prostat kanseri) doğru kaymaya başlamıştır. Biyomarker tabanlı hassas tıp yaklaşımları, hastaların bireysel özelliklerine göre en etkili tedavileri seçmeyi amaçlamaktadır(2).

Biyomarker tabanlı hassas tıp yaklaşımları, metastatik prostat kanserinin tedavisinde önemli bir umut vadetmektedir. Bu yaklaşımların geliştirilmesi için daha fazla araştırmaya ihtiyaç vardır (3, 4).

METASTATİK KASTRASYON DUYARLI PROSTAT KANSERİNDE HEDEFLİ TEDAVİLER

Metastatik hormon duyarlı prostat kanseri (mHSPC), prostat kanserinin vücudun diğer bölgelerine yayıldığı, ancak hormon tedavisine hala yanıt verdiği bir tür prostat kanseridir. mHSPC, prostat kanserinin en yaygın görülen türüdür. Prostat kanseri teşhisi konan erkeklerin yaklaşık %30'u mHSPC ile teşhis edilir (5).

¹ Uzm. Dr.,Medipol mega üniversite Hastanesi, Medikal Onkoloji Kliniği, hm1635@hotmail.com, ORCID iD:0000-0001-9584-0827

ilerlemelerle birlikte, biyobelirteçleri daha iyi geliştirmek, hasta içi ve hastalar arası heterojenliği yenmek ve ortaya çıkan direnç mekanizmalarıyla mücadele etmek için bir dizi yeni fırsat ve karşılanmamış ihtiyaçlar ortaya çıkması sonucunda ileri çalışmaların yapılması gerekliliğini ortaya koydu.

KAYNAKLAR

1. Yamada, Y. and H. Beltran, The treatment landscape of metastatic prostate cancer. *Cancer letters*, 2021. 519: p. 20-29.
2. Rawla, P., Epidemiology of prostate cancer. *World journal of oncology*, 2019. 10(2): p. 63.
3. Cai, Q., et al., Estimates of over-time trends in incidence and mortality of prostate cancer from 1990 to 2030. *Translational andrology and urology*, 2020. 9(2): p. 196.
4. Pishgar, F., et al., Global, regional and national burden of prostate cancer, 1990 to 2015: results from the global burden of disease study 2015. *The Journal of urology*, 2018. 199(5): p. 1224-1232.
5. Bitkin, A., et al., Modern tedavi yöntemleriyle metastatik prostat kanserli hastaların seyri değişti mi? *The New Journal of Urology*, 2013. 8(3): p. 12-18.
6. Sweeney, C.J., et al., Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. *New England Journal of Medicine*, 2015. 373(8): p. 737-746.
7. Fizazi, K., et al., Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. *The Lancet Oncology*, 2019. 20(5): p. 686-700.
8. Huggins, C. and C.V. Hodges, Studies on prostatic cancer. *Cancer res*, 1941. 1(4): p. 293-297.
9. Desai, M.M., et al., Trends in incidence of metastatic prostate cancer in the US. *JAMA Network Open*, 2022. 5(3): p. e222246-e222246.
10. Davis, I.D., et al., Enzalutamide with standard first-line therapy in metastatic prostate cancer. *New England Journal of Medicine*, 2019. 381(2): p. 121-131.
11. Armstrong, A.J., et al., ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. *Journal of Clinical Oncology*, 2019. 37(32): p. 2974.
12. Chi, K.N., et al., Apalutamide for metastatic, castration-sensitive prostate cancer. *New England Journal of Medicine*, 2019. 381(1): p. 13-24.
13. Tannock, I.F., et al., Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. *New England Journal of Medicine*, 2004. 351(15): p. 1502-1512.
14. Petrylak, D.P., et al., Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. *New England Journal of Medicine*, 2004. 351(15): p. 1513-1520.
15. James, N.D., et al., Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. *The Lancet*, 2016. 387(10024): p. 1163-1177.
16. Hussain, M., et al., Darolutamide plus androgen-deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer by disease volume and risk subgroups in the phase III ARASENS trial. *Journal of Clinical Oncology*, 2023. 41(20): p. 3595-3607.
17. De Bono, J.S., et al., Abiraterone and increased survival in metastatic prostate cancer. *New England Journal of Medicine*, 2011. 364(21): p. 1995-2005.

18. Fizazi, K., et al., Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. *The lancet oncology*, 2012. 13(10): p. 983-992.
19. Logothetis, C.J., et al., Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. *The lancet oncology*, 2012. 13(12): p. 1210-1217.
20. Ryan, C.J., et al., Abiraterone in metastatic prostate cancer without previous chemotherapy. *New England Journal of Medicine*, 2013. 368(2): p. 138-148.
21. Scher, H.I., et al., Increased survival with enzalutamide in prostate cancer after chemotherapy. *New England Journal of Medicine*, 2012. 367(13): p. 1187-1197.
22. Beer, T.M., et al., Enzalutamide in metastatic prostate cancer before chemotherapy. *New England Journal of Medicine*, 2014. 371(5): p. 424-433.
23. Beer, T.M., et al., Enzalutamide in men with chemotherapy-naïve metastatic castration-resistant prostate cancer: extended analysis of the phase 3 PREVAIL study. *European urology*, 2017. 71(2): p. 151-154.
24. Turner, N., A. Tutt, and A. Ashworth, Hallmarks of 'BRCAness' in sporadic cancers. *Nature reviews cancer*, 2004. 4(10): p. 814-819.
25. Lee, J., J. Ledermann, and E. Kohn, PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies. *Annals of oncology*, 2014. 25(1): p. 32-40.
26. Kaelin Jr, W.G., The concept of synthetic lethality in the context of anticancer therapy. *Nature reviews cancer*, 2005. 5(9): p. 689-698.
27. Markowski, M.C. and E.S. Antonarakis, BRCA1 versus BRCA2 and PARP inhibitor sensitivity in prostate cancer: more different than alike? *Journal of Clinical Oncology*, 2020. 38(32): p. 3735.
28. Mateo, J., et al., DNA-repair defects and olaparib in metastatic prostate cancer. *New England Journal of Medicine*, 2015. 373(18): p. 1697-1708.
29. Abida, W., et al., Non-BRCA DNA damage repair gene alterations and response to the PARP inhibitor rucaparib in metastatic castration-resistant prostate cancer: analysis from the phase II TRITON2 study. *Clinical Cancer Research*, 2020. 26(11): p. 2487-2496.
30. Michl, J., J. Zimmer, and M. Tarsounas, Interplay between Fanconi anemia and homologous recombination pathways in genome integrity. *The EMBO journal*, 2016. 35(9): p. 909-923.
31. de Bono, J., et al., Olaparib for metastatic castration-resistant prostate cancer. *New England Journal of Medicine*, 2020. 382(22): p. 2091-2102.
32. Abida, W., et al., Rucaparib in men with metastatic castration-resistant prostate cancer harboring a BRCA1 or BRCA2 gene alteration. *Journal of Clinical Oncology*, 2020. 38(32): p. 3763.
33. Fizazi, K., et al., Rucaparib or physician's choice in metastatic prostate cancer. *New England Journal of Medicine*, 2023. 388(8): p. 719-732.
34. Smith, M.R., et al., Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial. *The Lancet Oncology*, 2022. 23(3): p. 362-373.
35. Mehra, N., et al., Talazoparib, a poly (ADP-ribose) polymerase inhibitor, for metastatic castration-resistant prostate cancer and DNA damage response alterations: TALAPRO-1 safety analyses. *The oncologist*, 2022. 27(10): p. e783-e795.
36. Nicolosi, P., et al., Prevalence of germline variants in prostate cancer and implications for current genetic testing guidelines. *JAMA oncology*, 2019. 5(4): p. 523-528.
37. de Bono, J.S., et al., Randomized phase II study evaluating Akt blockade with ipatasertib, in combination with abiraterone, in patients with metastatic prostate cancer with and without PTEN loss. *Clinical Cancer Research*, 2019. 25(3): p. 928-936.